.png "Insmed (NASDAQ: INSM)")
Today, a Director at Insmed (INSM), Melvin Sharoky, bought shares of INSM for $320.1K.
Following this transaction Melvin Sharoky’s holding in the company was increased by 9.02% to a total of $4.04 million. In addition to Melvin Sharoky, 3 other INSM executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Insmed has an average volume of 552K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $43.50, reflecting a 172.0% upside. Starting in August 2018, INSM received 11 Buy ratings in a row. Four different firms, including Cowen & Co. and Credit Suisse, currently also have a Buy rating on the stock.
The insider sentiment on Insmed has been positive according to 21 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Melvin Sharoky’s trades have generated a 38.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.
